Management of corticosteroid-induced osteoporosis.
Treatment with corticosteroids can adversely affect bone metabolism. In particular, it lowers bone mineral density (BMD) and increases the likelihood of fragility fractures, the hallmarks of osteoporosis, hence the term 'corticosteroid-induced osteoporosis'. Since corticosteroids are used for a wide variety of inflammatory conditions, corticosteroid-induced osteoporosis represents a substantial disease burden. Here we aim to provide advice on prophylaxis and treatment for osteoporosis in adults receiving corticosteroid therapy.
D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D000328:Adult; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D002136:Calcium, Dietary / Q000008:administration & dosage; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D010024:Osteoporosis / Q000139:chemically induced* / Q000188:drug therapy; D012017:Referral and Consultation; D019379:Teriparatide / Q000008:administration & dosage / Q000009:adverse effects; D014807:Vitamin D / Q000008:administration & dosage
D000305:Adrenal Cortex Hormones; D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D004164:Diphosphonates; D019379:Teriparatide; D014807:Vitamin D